您好,欢迎来到半岛电竞官方网址 ! [ 登录] [ 免费注册]
半岛电竞官方网址
位置: 首页> 半岛bd体育手机客户端 库> Cdk1/2 Inhibitor III
立即咨询
咨询类型:
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
Cdk1/2 Inhibitor III
本半岛bd体育手机客户端 不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Cdk1/2 Inhibitor III图片
CAS NO: 443798-47-8
包装与价格:
包装 价格(元)
1mg 电议
5mg 电议
10mg 电议

半岛bd体育手机客户端 介绍

化学性质

Physical Appearance A solid
Storage Store at -20°C
M.Wt 425.4
Cas No. 443798-47-8
Formula C15H13F2N7O2S2
Solubility ≤10mg/ml in DMSO
Chemical Name 5-amino-3-[[4-(aminosulfonyl)phenyl]amino]-N-(2,6-difluorophenyl)-1H-1,2,4-triazole-1-carbothioamide
Canonical SMILES NC1=NC(NC2=CC=C(S(N)(=O)=O)C=C2)=NN1C(NC3=C(F)C=CC=C3F)=S
运输条件 蓝冰运输或根据您的需求运输。
一般建议 为了使其更好的溶解,请用37℃加热试管并在超声波水浴中震动片刻。不同厂家不同批次半岛bd体育手机客户端 溶解度各有差异,仅做参考。若实验所需浓度过大至半岛bd体育手机客户端 溶解极限,请添加助溶剂助溶或自行调整浓度。溶液形式一般不宜长期储存,请尽快用完。

资料参考

IC50: 0.6 and 0.5 nM forCdk1/cyclin B and Cdk2/cyclin A, respectively

Cdk1/2 Inhibitor III is a Cdk inhibitor.

Cyclin-dependent kinases (CDKs) are a family members of serine-threonine protein kinases responsible for regulation of the eukaryotic cell cycle. Their timed activation guides cells via the cell cycle and ensures the accurate execution of cell division.

In vitro: Cdk1/2 Inhibitor III was identified as a cell-permeable inhibitor of Cdk1/cyclin B and Cdk2/cyclin A and could less potently inhibit CDC2-like kinases 1 and 3, VEGFR2, and GSK-3β. Cdk1/2 Inhibitor III was found to be lack of effect against a panel of other kinases. Moreover, Cdk1/2 Inhibitor III could block the growth of various cancer cell lines (IC50 values range from 20 to 92 nM) [1].

In vivo: The in-vivo efficacy of compound 3b, a structurally close Cdk1/2 Inhibitor III analog, was examined in the A375 human melanoma cell xenograft model. Doses at 125, 100, and 75 mg/kg were administered once a day for 32 days and tumor size was measured every 4 days. The results showed that in the 125 mg/kg group, there was one nontreatment-related death but the remaining four animals experienced stable disease. In addition, compound 3b administered at 100 and 75 mg/kg led to mean day of survival values of 50.1 and 48.5 days, respectively, with only one treatment-related death in the 100 mg/kg group [1].

Clinical trial: So far, no clinical study has been conducted.

Reference:
[1] Lin, R. ,Connolly, P.J.,Huang, S., et al. 1-Acyl-1H-[1,2,4]triazole-3,5-diamine analogues as novel and potent anticancer cyclin-dependent kinase inhibitors: Synthesis and evaluation of biological activities. Journal of Medicinal Chemistry 48(13), 4208-4211 (2005).

Baidu
map